Business Wire

B2BROKER

14.12.2021 11:02:59 CET | Business Wire | Press release

Share
B2Broker Seals European Presence with CySEC-Regulated Provider B2Prime

B2Broker , a leading technology and liquidity provider within the Forex/CFDs and Digital Currency industries, has confirmed that it has expanded its global reach by establishing a presence in the heavily EU regulated Forex /CFDs market through B2Prime , a Cyprus based Financial Institution authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005172/en/

B2Broker now has a vested interest in B2Prime after fulfilling the necessary legal requirements for the required ownership changes. The new owners of B2Prime are Arthur Azizov, founder of B2Broker Group of Companies and Evgeniya Mykulyak, co-founder of B2Broker Group of Companies. Nick Chrysochos becomes the CEO of B2Prime. The move confirms the group’s commitment to providing its investment related services on a global scale through a Liquidity Provider regulated by one of the most well respected and recognised Financial Market Supervisory Authorities.

About B2Prime

B2Prime is a global regulated Prime of Prime (PoP) Multi-Asset Liquidity Provider for institutional and professional clients across the whole spectrum of the financial markets. Its core investment services consist of leveraged derivative products in CFDs (Forex, metals, commodities, shares, indices and cryptocurrencies).

B2Broker Group of Companies

B2Broker is a global brand with a solid reputation in the B2B sphere as one of the most in-demand technology and liquidity providers for Forex and crypto brokers, crypto exchanges and other financial services entities. The company offers a wide range of services including Crypto/Forex/CFD liquidity, Crypto/Forex Broker turnkey solutions, crypto payment processing (B2BinPay), MT4/5 white label solutions, B2Core (Trader’s Room) , B2Trader (Matching Engine) and liquidity on over 800 trading instruments across the entire spectrum of assets.

Headquartered in Moscow, B2Broker has several years of operational experience with 10 offices in 8 countries across Russia, Europe, Asia and MENA. A total of 7 licences to its name including FCA, AEMI and Central Bank of Russia, allows B2Broker to serve clients across 50 countries, offering Forex liquidity distribution and a range of other services to the Forex, Crypto and Securities industries. The company has secured a large portfolio of well-known global clients in the financial services industry with plans to further increase company representation and visibility across the globe.

What the News Means For Clients

CySEC is Cyprus’ financial regulator which provides a framework within which the country’s licenced financial services firms are obliged to operate. As a CySEC regulated broker, B2Prime must adhere to the strictest financial market regulatory standards, including capital adequacy requirements, segregation of client funds and transparency of business operations.

Clients residing in the EU, UK and several other 3rd country jurisdictions can now be safely onboarded under the EU MiFID II regulatory standards. B2Broker can now expand its footprint in the European Union and provide clients with the opportunity to experience the organisation’s full product and service offering through an EU financial services brokerage licence, while positioning itself on an accelerated global growth path.

B2Broker Group of Companies CEO, Arthur Azizov, commented, “We are delighted that B2Prime has secured CySEC approval. The licence gives us the scope to provide institutional grade liquidity to clients in over 30 countries. Meanwhile, our clients will be able to benefit from an enhanced level of protection, safe in the knowledge that they have the backing of a world-leading, multi-regulated technology and liquidity provider. We expect that having now secured CySEC’s authorisation to provide our investment liquidity services, it will help us establish our place in this space as one of the strongest and most reliable organisations where clients can feel at ease when trading with us”.

B2Prime’s owner and Executive Director, Evgeniya Mykulyak, co-founder of B2Broker Group commented, “My vision is to make B2Prime one of the most solid and reliable financial services companies in the Forex space with a high standard of service provision being our key focus. I look forward to exploring the many new opportunities available to us in Europe and to welcoming new clients on board. Our efforts will include the introduction of new trading platforms for connection as well as the continued rollout of our Prime of Prime liquidity services. We are already building a strong liquidity provision network in the European market and have established relationships with major Prime Brokers. Furthermore, we plan to become a member of several exchanges, all in all, making B2Prime a major player in the financial services industry”.

B2Prime CEO, Nick Chrysochos added, “With Artur Azizov’s long experience and solid credentials in the Forex and Crypto space and Evgeniya Mykulyak’s deep industry know-how and clear vision for the company, we will be able to provide advanced, cutting-edge technology so that our clients can trade with the reassurance of knowing that their trading activities are managed by a reputable firm that adheres to the most stringent regulatory standards of CySEC”.

Final Word

BPrime has already opened the door to receiving new clients and can connect brokers via OneZero, MT5 and PrimeXM platforms to offer trading on 115 Forex pairs including 22 Crypto CFD pairs, Spot Metals, Indices and Spot Energies.

The latest licence acquisition is a part of B2Broker’s overall strategic plan to have a presence in all the major jurisdictions, focusing on the goal of becoming a global liquidity provider. The corresponding launch of commercial operations in Cyprus is also a testament to the company’s ongoing success and growth, where it will continue to provide some of the best liquidity and trading services in the industry.

Link:

ClickThru

Social Media:

https://www.facebook.com/b2broker

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release

Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly

SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release

The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter

Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release

Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye